Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)7.47m
- Net income in USD-73.06m
- Incorporated2004
- Employees83.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | 155.72m | -415.73m | 783.37m | 380.00 | -- | 10.57 | -- | 5.03 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Savara Inc | 0.00 | -64.49m | 785.94m | 37.00 | -- | 5.42 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 805.85m | 116.00 | -- | 3.05 | -- | -- | -1.62 | -1.97 | -0.0092 | 3.92 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -99.34m | 807.13m | 75.00 | -- | 3.41 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -121.21m | 807.82m | 116.00 | -- | 1.86 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 812.39m | 53.00 | -- | 2.18 | -- | 251.98 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 835.23m | 300.00 | -- | 2.33 | -- | 4.36 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Nuvation Bio Inc | 0.00 | -68.87m | 837.91m | 159.00 | -- | 1.25 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
| Immunome Inc | 12.68m | -232.03m | 838.96m | 55.00 | -- | 2.92 | -- | 66.15 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| 89bio Inc | 0.00 | -165.03m | 853.97m | 70.00 | -- | 1.62 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 858.61m | 164.00 | -- | 4.29 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Mesoblast Ltd (ADR) | 7.47m | -73.06m | 864.09m | 83.00 | -- | 0.7361 | -- | 115.74 | -1.44 | -1.44 | 0.1388 | 10.03 | 0.0112 | -- | 3.71 | 89,951.80 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
| 4D Molecular Therapeutics Inc | 20.45m | -104.56m | 941.00m | 171.00 | -- | 1.55 | -- | 46.01 | -2.36 | -2.36 | 0.4841 | 11.74 | 0.0468 | -- | -- | 139,136.00 | -23.93 | -32.67 | -24.71 | -34.90 | -- | -- | -511.20 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 941.40m | 117.00 | -- | 19.70 | -- | 41.00 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 942.82m | 82.00 | -- | 3.18 | -- | 429.53 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Data as of Jul 22 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: US Dollar USD
0.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Group One Trading LPas of 31 Mar 2024 | 143.67k | 0.13% |
| Summit X LLCas of 31 Mar 2024 | 139.75k | 0.12% |
| Penbrook Management LLCas of 31 Mar 2024 | 125.18k | 0.11% |
| Regal Funds Management Pty Ltd.as of 31 Mar 2024 | 117.24k | 0.10% |
| Prosperity Wealth Management, Inc.as of 31 Mar 2024 | 77.35k | 0.07% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 62.16k | 0.05% |
| Chase Investment Counsel Corp.as of 31 Mar 2024 | 59.60k | 0.05% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 59.21k | 0.05% |
| HRT Financial LLCas of 31 Mar 2024 | 57.82k | 0.05% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 57.51k | 0.05% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
